CN1899479A - Chinese medicine compound preparation for treating osteoporosis after menopause and its preparation - Google Patents
Chinese medicine compound preparation for treating osteoporosis after menopause and its preparation Download PDFInfo
- Publication number
- CN1899479A CN1899479A CN 200610090199 CN200610090199A CN1899479A CN 1899479 A CN1899479 A CN 1899479A CN 200610090199 CN200610090199 CN 200610090199 CN 200610090199 A CN200610090199 A CN 200610090199A CN 1899479 A CN1899479 A CN 1899479A
- Authority
- CN
- China
- Prior art keywords
- preparation
- fructus
- salviae miltiorrhizae
- rhizoma
- radix salviae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The compound Chinese medicine preparation for treating osteoporosis after menopause is prepared with drynaria rhizome, dodder seed, malaytea scurfpea fruit, wolfberry fruit, raspberry and other Chinese medicinal materials.
Description
Technical field:
The present invention relates to a kind of compound Chinese medicinal preparation and preparation thereof for the treatment of postmenopausal osteoporosis, particularly use the Chinese medicine Rhizoma Drynariae, Semen Cuscutae, Fructus Psoraleae, Fructus Lycii, Fructus Rubi, Colla Corii Asini, Rhizoma Cyperi, Radix Salviae Miltiorrhizae, the Chinese medicine preparation of feedstock production such as Radix Achyranthis Bidentatae.
Background technology:
Though after 40～50 years old, the situation that bone mineral content descends gradually with age growth can appear in the men and women, the women will occur after women's menopause osteoporosis taking place easily because the decline of postmenopausal estrogen level makes bone loss apparently higher than the male.Now, various countries women's life-span all is the trend that increases year by year, prevents that the generation of postmenopausal osteoporosis from having caused the concern of countries in the world.Osteoporosis is that the bone amount of general reduces, and changes and the increase of skeleton fragility with bone micro-structure, and the disease of fracture easily takes place.Its pathological characteristic is the minimizing of bone mineral content and bone matrix composition equal proportion, the cortical bone attenuation, and bone trabecula reduces and attenuates.Postmenopausal osteoporosis wherein, main cause is an estrogen deficiency, based on female patient, age of onset, shows the bone amount to lose rapidly between year at 50-70, and it is more obvious that spongy bone is lost, fracture mostly occurs the vertebral body based on spongy bone proximal femur and distal radius.Behind the postmenopausal women osteoporosis can take place, depend primarily on the speed of the height and the bone loss of peak bone mass.
The etiology of postmenopausal osteoporosis
Peak bone mass depends primarily on inherited genetic factors, but environmental factors also influences peak bone mass, as dietary habit and motion.The absorption of high calcium food, can influence ripe bone bone mineral content 6%.Discover, adhere to taking exercise every day, and sports amount its bone mineral content of people of being higher than average magnitude to be higher than activity and is lower than average magnitude person.A large amount of smokings and its peak bone mass of alcoholic are all lower.After women's menopause, estrogen level sharply descends, and bone loss is logarithm to be increased.
Use the history in existing more than 10 year of generation of hormonal supplementation therapy prevention of osteoporosis disease and fracture clinically, but one of U.S. WHI in 2002 extensive, multicenter, the clinical experimental study result's of contrast announcement have at random caused the disputes that many relevant postmenopausal women use the controversies in hormone replacement in the elderly protect against osteoporosis.In the research of WHI, 16608 of average 5.2 years 50～79 years old postmenopausal women have been followed up a case by regular visits to altogether, found that: unite the prevention that hormone replacement therapy (HRT) should not be used for postmenopausal women's cardiovascular disease continuously, when prevention postmenopausal women osteoporosis, should be taken into account mammary gland and cardiovascular disease risk.
Doctor trained in Western medicine to the treatment of primary disease generally adopt gonadal hormone, replenish the calcium, activated vitamin D etc., but the prolonged application hormone can bring serious side reaction, replenishing of calcium and vitamin is difficult to control again on dosage.Therefore the Chinese medicine osteoporosis has been compared its tangible characteristics and advantage with western modern medicine, and existing Chinese medicine in recent years is described below at the research overview aspect the treatment postmenopausal osteoporosis: motherland's medical science thinks, PMOP be suffer from a deficiency of the kidney due to [1]; Therefore the Chinese medicine based on the kidney invigorating is the research direction of preventing and treating PMOP at present.In motherland's medical science, there is no the osteoporosis name of disease, but according to the mutual relation of bone and osteoporosis, pathological change, symptom description etc., osteoporosis surely belongs to categories such as motherland's medical science it " atrophic debility of bones ", " bone is withered ".Discover that the Testudinis silk is mended osteocomma and had similar estrogen-like effects, can improve the early stage women's of menopause nephrasthenia syndrome, and have the effect [2] that promotes calcium metabolism, adjusts calcium-regulating hormone.
Chinese medicine has bigger potentiality and advantage aspect the osteoporosis preventing and treating.(1) curative effect height not only can make the sclerotin reparation, and can also improve the biomechanics [3,4] of sclerotin and bone, alleviates or the elimination symptom.(2) side effect is little, and low price can be taken for a long time.(3) effect comprehensively can endocrine regulation, the functional status of a plurality of systems such as immunity, obtain the Comprehensive Treatment effect, and late result is stable.
The dialectical Qi Shi [5] of osteoporosis is according to theory of Chinese medical science, in conjunction with the clinical characters of disease, osteoporosis is divided into 4 types distinguishes and control, be i.e. damage of kidney-YIN type, decline of kidney-YANG type, qi-deficiency of spleen and stomach, QIXUELIANGXU type.Liu Shi [4] is divided into 6 kinds of pattern of syndrome such as drink, exogenous cold interior-heat, marrow forceless pulse numbness in the hepatic and renal YIN deficiency, blood deficiency water Sheng, the cold-damp of suffering from a deficiency of the kidney, the exterior deficiency with osteoporosis.
The treatment Deng Shi [6] of treatment 4.1 specific prescription and medications of osteoporosis is the Therapeutic Principle with kidney-replenishing, nourishing kidney-yin, bone and muscle strengthening, with invigorating the kidney and strengthening the bones soup (Radix Rehmanniae, Rhizoma Alismatis, Poria, Radix Morindae Officinalis, each 10g of Herba Epimedii, Rhizoma Dioscoreae, Fructus Corni, each 15g of Rhizoma Drynariae, Cortex Cinnamomi 3g, Colla cornus cervi (melting), each 6g of Colla Plastri Testudinis (molten).45 routine patients with osteoporosis are treated, the treatment half a year after total effective rate reach 95.6%.Guo Shi [7] subtracts (Radix Rehmanniae Preparata 20g, Caulis Spatholobi 25g, Cortex Acanthopancis 15g, Radix Codonopsis 15g, Rhizoma Drynariae 15g, Radix Glycyrrhizae Preparata 10g, each 10g of Testudinis deer two glue (molten) to intend invigorating function of kidney and strengthening bone Tonga certainly.) treatment postmenopausal osteoporosis 85 examples, spinal column has the wedge shape changer to add Radix Notoginseng powder 5g; The double rheumatism person of holding under the arm adds Qiang, each 10g of Radix Angelicae Pubescentis, Radix Clematidis 15g, grey, each 15g of the Rhizoma Atractylodis Macrocephalae; The easypro person of double person's back adds Radix Puerariae 25g, Rhizoma Et Radix Notopterygii 10g.The result shows: produce effects 75% in 85 examples of treatment back; Take a turn for the better 21%.Especially to lumbago and backache, the alleviation of symptoms such as malaise and elimination effect are more obvious.4.2 improve [8] utilization kidney tonifying, essence replenishing electuaries (Herba Cistanches, Radix Polygoni Multiflori, the Rhizoma Atractylodis Macrocephalae, Placenta Hominis, Fructus Psoraleae, Radix Achyranthis Bidentatae, Semen Cuscutae, Os Draconis (calcined), Concha Ostreae (calcined), Flos Chrysanthemi etc.) treatment 30 routine postmenopausal osteoporosiss such as Chinese medicine dosage form Amur; Estrogen group 20 examples are treated with diethylstilbestrol; Symptomatic treatment group 30 examples adopt the additional calcium preparation or the analgesics of discontinuity.The result shows: the kidney tonifying, essence replenishing electuary can improve the disease of suffering from a deficiency of the kidney effectively, alleviates lumbar and back pain, increases the bone density of forearm chi, radius, and this side also has inhibition bone forfeiture effect, and protect against osteoporosis is prevented and treated meaning.Liu Shi [9] adopts bone recovering capsule (Herba Epimedii, Herba Cistanches, Radix Angelicae Sinensis, Radix Codonopsis, the Radix Polygoni Multiflori, Radix Salviae Miltiorrhizae, the Radix Astragali etc.) treatment 65 routine patients with postmenopausal osteoporosis, finds that this capsule all has curative effect preferably for improving patient's pain symptom, sign and raising forearm oar, ulna and lumbar spine bmd.
The main neuter simulation postmenopausal osteoporosis that adopts of the modern zoopery of osteoporosis and herbal pharmacology research, centering pharmaceutically active ingredient and compound recipe carry out pharmaceutical research.Xie Shi etc. [10] are means with the osseous tissue morphometry, adopt the close bone liquid of the kidney invigorating (Herba Epimedii, the Cortex Eucommiae, Semen Juglandis, Radix Rehmanniae, big pollen, Radix Achyranthis Bidentatae etc.) that ovariectomized rat is carried out lumbar injection, set up sham operated rats, estrogen group, oophorectomize group and saline group to compare simultaneously.The result shows that the close bone liquid of Chinese drug-treated group the kidney invigorating can effectively stop losing of ovariectomized rat bone amount.Luo Shi etc. [11] are divided into treatment by Chinese herbs group, model group and normal control group at random with 16 female new zealand rabbits, and preceding two groups of methods with artificial castration are after 6 months, make high conversion type osteoporosis model after the menopause.The result shows: treatment by Chinese herbs group bone amount increases, and the bone formation rate increases, and area of tetracycline label blood and bone formation face significantly increase, and illustrates that the strengthening spleen, tonifying kidney method can improve the bone metabolism conversion, increases the bone amount, prolongs the osteoblast skeletonization phase, recovers the normal function of skeleton.Feng Shi etc. [12] have carried out experimentation with the influence of bone recovery oral liquid to castrated rats biomechanics aspect.The result shows in the Chinese medicinal bone health, the castrated rats peak torque of low dose group is higher than model group, and then infer that the bone recovery oral liquid may promote building again of castrated rats bone structure, improve the internal structure of bone, thereby improve the mechanical performance of rat bone, the bearing capacity of osseous tissue is strengthened.
Show according to another modern pharmacological research: Herba Epimedii can enliven osteoblast, suppresses the absorption function of osteoclast, again can the protectiveness glandular tissue and the maintenance hormonal readiness; Radix Morindae Officinalis, Fructus Corni, Rhizoma Drynariae have the modulability hormonal action; Fructus Cnidii has gonadotropic Effect, in the estradiol ria-determination, further proves in the organic extract of Fructus Cnidii, contains the estradiol similar substance, can regulate the organism endocrine function.And Fructus Cnidii total coumarins has the effect of prevention castrated rats osteoporosis; Colla cornus cervi has the reduction muscle fatigue, promotes the new life of erythrocyte, hemoglobin, skein cell, promotes the effect of union of fracture.
The research of Chinese medicine aspect postmenopausal osteoporosis has obtained many important achievement, also sum up simultaneously many effective medication experiences, undoubtedly, Chinese medicine has bigger potentiality and advantage aspect protect against osteoporosis, main because: (1) traditional Chinese medical science is for transferring therapy, focus on integrally-regulatedly, transfer endogenous cause of ill.(2) curative effect height not only can make the bone reparation, and can also improve the biomechanical property of bone amount and bone, alleviates or the elimination symptom.(3) side effect is little, and is cheap, can take for a long time.(4) effect comprehensively can endocrine regulation, the functional status of a plurality of systems such as immunity, play the purpose of Comprehensive Treatment, and late result is stable.
List of references
[1] Wei Shaobin, Yang Jialin. postmenopausal osteoporosis and the relation of suffering from a deficiency of the kidney. Chinese gerontology magazine, 1996,16 (6): 337～338
[2] Xie Lin, Guo Zhenqiu, Yao Gonghe, etc. the postmenopausal osteoporosis Chinese medical discrimination is analyzed. Chinese Medicine journal, 1999,14 (3): 35～39
[3] fourth Ramulus Cinnamomi, Ceng Tianshu, Zhou Yong.Kidney-nourishing tcm drug is to the research of castrated rats biomechanics influence.China's orthopedics and traumatology of Chinese medicine magazine, 1995,3 (1): 1
[4] Liu Pei.The Chinese medicine of postmenopausal osteoporosis is inquired into.China's Pharmaceutical.2002，(6)：67
[5] Qi Zhenxi. the Coryza Treated by Syndrome Differentiation postmenopausal osteoporosis. Chinese orthopedics and traumatology of Chinese medicine magazine, 1998,6 (3): 28～29
[6] Deng Weimin, He Yangshu, Feng Yongjia, etc. the clinical research of invigorating the kidney and strengthening the bones soup treatment postmenopausal osteoporosis. Chinese Chinese medicine science and technology, 1997,4 (2): 70～72
[7] Guo Meiying, An Hangfang, Wang Zhihou, etc. invigorating function of kidney and strengthening bone soup treatment postmenopausal osteoporosis 85 examples. Changchun Traditional Chinese Medical College's journal, 1995,11 (2): 41～42
[8] execute Qi, Xie Keyong. the clinical research of kidney tonifying, essence replenishing method control postmenopausal osteoporosis, journal of shanghai Chinese medicine, 1996, (10): 2～7
[9] Liu Qingsi, Chen Zhongze, Li Xiaonong, etc. bone recovering capsule treatment postmenopausal osteoporosis 65 routine observation of curative effect. the new traditional Chinese medical science, 1995,27 (10): 31～32
[10] Xie Jing, Du Jingyuan, Shen Lin, etc. the close bone liquid of the kidney invigorating acts on bone histomorphometry's research of ovariectomized rat. Chinese orthopedics and traumatology of Chinese medicine magazine, 1995,3 (6): 1～3
[11] Luo Weimin, Fu Shicong, Du Ning, etc. the meteorological study of strengthening spleen, tonifying kidney method control postmenopausal osteoporosis. Chinese orthopedics and traumatology of Chinese medicine magazine, 1995,3 (2): 14
[12] Feng Xin send, Shao Min, and Huang Hongxing, etc. the Chinese medicinal bone health is to the influence of castrated rats biomechanics. Traditional Chinese Medicine University Of Guangzhou's journal, 1998,15 (3): 211～213
Treat the Chinese medicine of postmenopausal osteoporosis in the market, some belongs to cures the symptoms, not the disease, and some uses expensive composition, and some is cut and interrupt using owing to uncertain therapeutic efficacy in application process.The invention provides a kind of determined curative effect, safe ready, little, the cheap pure traditional Chinese compound medicine of side effect, more superior than prior art.
Summary of the invention:
The invention provides a kind of compound Chinese medicinal preparation and preparation thereof for the treatment of postmenopausal osteoporosis, said preparation is to use Rhizoma Drynariae, Semen Cuscutae, and Fructus Psoraleae, Fructus Lycii, Fructus Rubi, Colla Corii Asini, Rhizoma Cyperi, Radix Salviae Miltiorrhizae, Chinese medicines such as Radix Achyranthis Bidentatae are feedstock production.
The present invention on the prior art basis, with Rhizoma Drynariae, Semen Cuscutae, Fructus Psoraleae, Fructus Lycii, Fructus Rubi, Colla Corii Asini, Rhizoma Cyperi, Radix Salviae Miltiorrhizae, the pharmaceutical preparation that the Radix Achyranthis Bidentatae compatibility is succeeded in developing, several medicine additions have synergism.
Compound preparation of the present invention, its raw material of Chinese medicine is composed as follows:
Rhizoma Drynariae 1-20 part, Semen Cuscutae 2-25 part, Fructus Psoraleae 2-20 part, Fructus Lycii 1-22 part, Fructus Rubi 2-24 part, Colla Corii Asini 1-20 part, Rhizoma Cyperi 3-20 part, Radix Salviae Miltiorrhizae 2-22 part, Radix Achyranthis Bidentatae 2-22 part.
Preferably:
Rhizoma Drynariae 1-10 part, Semen Cuscutae 1-10 part, Fructus Psoraleae 1-10 part, Fructus Lycii 1=10 part, Fructus Rubi 1-10 part, Colla Corii Asini 1-10 part, Rhizoma Cyperi 1-10 part, Radix Salviae Miltiorrhizae 1-10 part, Radix Achyranthis Bidentatae 1-10 part.
More preferably:
Rhizoma Drynariae 1-5 part, Semen Cuscutae 1-5 part, Fructus Psoraleae 1-5 part, Fructus Lycii 1-5 part, Fructus Rubi 1-5 part, Colla Corii Asini 1-5 part, Rhizoma Cyperi 1-5 part, Radix Salviae Miltiorrhizae 1-5 part, Radix Achyranthis Bidentatae 1-5 part.
Particularly preferably be:
Rhizoma Drynariae 1-3 part, Semen Cuscutae 1-3 part, Fructus Psoraleae 1-3 part, Fructus Lycii 1-3 part, Fructus Rubi 1-3 part, Colla Corii Asini 1-3 part, Rhizoma Cyperi 1-3 part, Radix Salviae Miltiorrhizae 1-3 part, Radix Achyranthis Bidentatae 1-3 part.
Most preferably:
Rhizoma Drynariae 1-2 part, Semen Cuscutae 1-2 part, Fructus Psoraleae 1-2 part, Fructus Lycii 1-2 part, Fructus Rubi 1-2 part, Colla Corii Asini 1-2 part, Rhizoma Cyperi 1-2 part, Radix Salviae Miltiorrhizae 1-2 part, Radix Achyranthis Bidentatae 1-2 part.
In more than forming, weight is calculated with crude drug, as 470 parts of most preferred Fructus Psoraleaes, 250 parts of Semen Cuscutae, Colla Corii Asini 250,220 parts of Fructus Lycii, 220 parts of Radix Salviae Miltiorrhizaes, 220 parts of Rhizoma Cyperis, 220 parts of Fructus Rubies, 220 parts of Rhizoma Drynariae, 220 parts of Radix Achyranthis Bidentataes, wherein part is represented weight portion, every part if be unit with the gram, more than forms to can be made into 1000 doses of pharmaceutical preparatioies, described 1000 doses of fingers, the final drug preparation of making, as make 1000 of capsule preparations, 1000 in tablet, granule 1000 grams, injection 1000ml, 1000 of injections etc.
More than form to be by weight as proportioning, when producing, can increase or reduce according to corresponding proportion, as large-scale production can be unit with the kilogram, or be unit with the ton, small-scale production can be unit with the milligram also, weight can increase or reduce, but the constant rate of the raw medicinal herbs weight proportion between each composition.
The ratio of above weight proportion obtains through science screening, for especial patient, and as serious symptom or light disease, fat or modest patient, the proportioning of the amount of can corresponding adjustment forming increases or reduces being no more than 100%, and drug effect is constant.
Single medicinal material in more than forming also can be replaced by the suitable Chinese medicine with identical property of medicine, and its drug effect of the Chinese medicine preparation after the replacement is constant.
Chinese medicine preparation of the present invention is to process through extraction or other modes by the raw material of Chinese medicine that above-mentioned prescription is formed, and makes pharmaceutically active substance, subsequently, with this material is raw material, adds the medicine acceptable carrier when needing, and makes according to the routine techniques of galenic pharmacy.Described active substance can obtain by extracting raw material of Chinese medicine respectively, also can obtain by the co-extracted raw material of Chinese medicine, also can obtain by other modes, as: by pulverize, squeeze, calcine, grind, sieve, percolation, extraction, water are carried, alcohol extraction, ester are carried, methods such as ketone is carried, chromatography obtain, these active substances can be the material of extractum form, can be that dry extract also can be a fluid extract, make different concentration according to the different needs decision of preparation.
Pharmaceutically active substance in the Chinese medicine preparation of the present invention, its shared percentage by weight in preparation can be 0.1-99.9%, all the other are the medicine acceptable carrier.Pharmaceutical preparation of the present invention exists with unit dosage form, and described unit dosage form is meant the unit of preparation, as every of tablet, and capsular every capsules, every bottle of oral liquid, every bag of granule, every of injection etc., the present invention is granule preferably.
Chinese medicine preparation of the present invention, when being prepared into medicament, optionally add suitable medicine acceptable carrier, described medicine acceptable carrier is selected from: mannitol, sorbitol, sodium pyrosulfite, sodium sulfite, sodium thiosulfate, cysteine hydrochloride, TGA, methionine, vitamin C, the EDTA disodium, EDTA calcium sodium, the alkali-metal carbonate of monovalence, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulphuric acid, phosphoric acid, aminoacid, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, silicon derivative, cellulose and derivant thereof, alginate, gelatin, polyvinylpyrrolidone, glycerol, soil temperature 80, agar, calcium carbonate, calcium bicarbonate, surfactant, Polyethylene Glycol, cyclodextrin, beta-schardinger dextrin-, the phospholipid material, Kaolin, Pulvis Talci, calcium stearate, magnesium stearate etc.
Preparation of the present invention is determined usage and dosage according to patient's situation in use,
Chinese medicine preparation of the present invention can prepare by the following method.
More than nine the flavor medical materials, get Colla Corii Asini and be ground into fine powder, standby; Fructus Psoraleae, Radix Salviae Miltiorrhizae are doubly measured the 60-95% alcohol reflux 2-5 time with 2-10, and each 1-3 hour, filter, merging filtrate reclaims ethanol and is concentrated into the clear paste that relative density is 1.20～1.25 (60 ℃), and is standby; Rhizoma Cyperi is suitably pulverized, and adds 2-10 times of water gaging, soaks 1-3 hour, adds thermal distillation 3-10 hour and extracts volatile oil, and the aqueous solution after distillation device is in addition collected; The five tastes such as Fructus Psoraleae, Radix Salviae Miltiorrhizae, Rhizoma Cyperi medicinal residues and all the other Rhizoma Drynariae add 4-12 times of water gaging and decoct 2-6 time, decocted 1-4 hour for the first time, decocted 1-6 hour for the second time, collecting decoction, the centrifugal filtration of gradation, filtrate and above-mentioned aqueous solution merge, and amalgamation liquid is evaporated to the clear paste that relative density is 1.20～1.25 (60 ℃), and is standby; Merge above-mentioned clear paste, mixing, being evaporated to relative density is the thick paste of 1.28～1.30 (60 ℃), vacuum drying (60～65 ℃), be ground into fine powder, add donkey-hide gelatin fine powder, dextrin 250g, aspartame 25g, mixing, make granule with 50-95% ethanol, drying sprays into above-mentioned volatile oil, mixing, make 1000g, promptly get granule.
The function of preparation of the present invention cures mainly and is the kidney invigorating and essence nourishing, the hard bone of strong waist.Be used for women's osteosporosis after menopause disease and belong to the deficiency of kidney essence person, disease is seen lumbar and back pain, the foot knees soreness, and limb is soft weak, and is not durable upright, can not be prudent, dizziness and tinnitus, luxated tooth is sent out thin, nocturia, body distortion change is short etc.
Following data declaration beneficial effect of the present invention by experiment.
The specific embodiment:
Further specify the present invention by the following examples, but not as limitation of the present invention.
Embodiment 1:
Prescription: Fructus Psoraleae 350g, Semen Cuscutae 220g, Colla Corii Asini 250g, Fructus Lycii 220g, Radix Salviae Miltiorrhizae 250g, Rhizoma Cyperi 220g, Fructus Rubi 220g, Rhizoma Drynariae 220g, Radix Achyranthis Bidentatae 220g
Preparation method:
Fructus Psoraleae (350g), Radix Salviae Miltiorrhizae (250g) are measured 50% alcohol reflux secondaries with 6 times, and each 2 hours, filter, merging filtrate reclaims ethanol and also is concentrated into the clear paste that relative density is 1.20～1.25 (60 ℃), and is standby; Get Colla Corii Asini (250g) and be ground into fine powder, standby; Rhizoma Cyperi (220g) is suitably pulverized, and adds 4 times of water gagings, soaks 1 hour, adds thermal distillation and extracts volatile oil in 5 hours, and the aqueous solution after distillation device is in addition collected; The five tastes (being 220g) such as Fructus Psoraleae, Radix Salviae Miltiorrhizae, Rhizoma Cyperi medicinal residues and all the other Rhizoma Drynariae add 10 times of water gagings and decoct secondary, decocted 2 hours for the first time, decocted 2 hours for the second time, collecting decoction, the centrifugal filtration of gradation, filtrate and above-mentioned aqueous solution merge, and amalgamation liquid is evaporated to the clear paste that relative density is 1.10～1.25 (60 ℃), and is standby; Merge above-mentioned clear paste, mixing, being evaporated to relative density is the thick paste of 1.28～1.30 (60 ℃), vacuum drying (60～65 ℃), be ground into fine powder, add donkey-hide gelatin fine powder, dextrin 250g, aspartame 25g, mixing, make granule with 75% ethanol, drying sprays into above-mentioned volatile oil, mixing, make 1000g, promptly get granule.
Embodiment 2:
Prescription: Fructus Psoraleae 330g, Semen Cuscutae 210g, Colla Corii Asini 230g, Fructus Lycii 210g, Radix Salviae Miltiorrhizae 230g, Rhizoma Cyperi 240g, Fructus Rubi 230g, Rhizoma Drynariae 230g, Radix Achyranthis Bidentatae 240g
Preparation method is with embodiment 1
Embodiment 3:
Prescription: Fructus Psoraleae 340g, Semen Cuscutae 230g, Colla Corii Asini 210g, Fructus Lycii 230g, Radix Salviae Miltiorrhizae 250g, Rhizoma Cyperi 220g, Fructus Rubi 220g, Rhizoma Drynariae 225g, Radix Achyranthis Bidentatae 230g
Preparation method is with embodiment 1
Embodiment 4:
Prescription: Fructus Psoraleae 400g, Semen Cuscutae 240g, Colla Corii Asini 230g, Fructus Lycii 220g, Radix Salviae Miltiorrhizae 235g, Rhizoma Cyperi 230g, Fructus Rubi 235g, Rhizoma Drynariae 225g, Radix Achyranthis Bidentatae 230g
Preparation method is with embodiment 1
Embodiment 5: the preparation of tablet
Prescription: Fructus Psoraleae 430g, Radix Salviae Miltiorrhizae 270g, Colla Corii Asini 260g, Rhizoma Cyperi 230g, Radix Salviae Miltiorrhizae 220g, Rhizoma Cyperi 220g, medicinal residues 220g, Rhizoma Drynariae 220g, Radix Achyranthis Bidentatae 220g
Preparation method:
Fructus Psoraleae (430g), Radix Salviae Miltiorrhizae (270g) are measured 50% alcohol reflux secondaries with 6 times, and each 2 hours, filter, merging filtrate reclaims ethanol and also is concentrated into the clear paste that relative density is 1.20～1.25 (60 ℃), and is standby; Get Colla Corii Asini (260g) and be ground into fine powder, standby; Rhizoma Cyperi (230g) is suitably pulverized, and adds 4 times of water gagings, soaks 1 hour, adds thermal distillation and extracts volatile oil in 5 hours, and the aqueous solution after distillation device is in addition collected; The five tastes (being 220g) such as Fructus Psoraleae, Radix Salviae Miltiorrhizae, Rhizoma Cyperi medicinal residues and all the other Rhizoma Drynariae add 10 times of water gagings and decoct secondary, decocted 2 hours for the first time, decocted 2 hours for the second time, collecting decoction, the centrifugal filtration of gradation, filtrate and above-mentioned aqueous solution merge, and amalgamation liquid is evaporated to the clear paste that relative density is 1.10～1.25 (60 ℃), and is standby; Merge above-mentioned clear paste, mixing, being evaporated to relative density is the thick paste of 1.28～1.30 (60 ℃), vacuum drying (60～65 ℃), be ground into fine powder, add donkey-hide gelatin fine powder, dextrin 250g, aspartame 25g, mixing is made granule with 75% ethanol, dry, spray into above-mentioned volatile oil, tabletting promptly gets tablet.
Embodiment 6: the preparation of capsule
Prescription: Fructus Psoraleae 450g, Radix Salviae Miltiorrhizae 260g, Colla Corii Asini 240g, Rhizoma Cyperi 230g, Radix Salviae Miltiorrhizae 210g, Rhizoma Cyperi 210g, medicinal residues 210g, Rhizoma Drynariae 210g, Radix Achyranthis Bidentatae 210g
Preparation method:
Fructus Psoraleae (350g), Radix Salviae Miltiorrhizae (260g) are measured 50% alcohol reflux secondaries with 6 times, and each 2 hours, filter, merging filtrate reclaims ethanol and also is concentrated into the clear paste that relative density is 1.20～1.25 (60 ℃), and is standby; Get Colla Corii Asini (240g) and be ground into fine powder, standby; Rhizoma Cyperi (230g) is suitably pulverized, and adds 4 times of water gagings, soaks 1 hour, adds thermal distillation and extracts volatile oil in 5 hours, and the aqueous solution after distillation device is in addition collected; The five tastes (being 210g) such as Fructus Psoraleae, Radix Salviae Miltiorrhizae, Rhizoma Cyperi medicinal residues and all the other Rhizoma Drynariae add 10 times of water gagings and decoct secondary, decocted 2 hours for the first time, decocted 2 hours for the second time, collecting decoction, the centrifugal filtration of gradation, filtrate and above-mentioned aqueous solution merge, and amalgamation liquid is evaporated to the clear paste that relative density is 1.10～1.25 (60 ℃), and is standby; Merge above-mentioned clear paste, mixing, being evaporated to relative density is the thick paste of 1.28～1.30 (60 ℃), vacuum drying (60～65 ℃), be ground into fine powder, add donkey-hide gelatin fine powder, dextrin 250g, aspartame 25g, mixing is made granule with 75% ethanol, dry, spray into above-mentioned volatile oil, encapsulated, promptly get capsule.
Claims (10)
1, a kind of compound Chinese medicinal preparation for the treatment of postmenopausal osteoporosis is characterized in that, described preparation is by the Chinese medicine Rhizoma Drynariae, Semen Cuscutae, and Fructus Psoraleae, Fructus Lycii, Fructus Rubi, Colla Corii Asini, Rhizoma Cyperi, Radix Salviae Miltiorrhizae, Radix Achyranthis Bidentatae are feedstock production.
2, the preparation of claim 1 is characterized in that, wherein the weight proportion of each component is: Rhizoma Drynariae 1-20 part, Semen Cuscutae 2-25 part, Fructus Psoraleae 2-20 part, Fructus Lycii 1-22 part, Fructus Rubi 2-24 part, Colla Corii Asini 1-20 part, Rhizoma Cyperi 3-20 part, Radix Salviae Miltiorrhizae 2-22 part, Radix Achyranthis Bidentatae 2-22 part.
3, the preparation of claim 1 is characterized in that, wherein the weight proportion of each component is: Rhizoma Drynariae 1-10 part, Semen Cuscutae 1-10 part, Fructus Psoraleae 1-10 part, Fructus Lycii 1=10 part, Fructus Rubi 1-10 part, Colla Corii Asini 1-10 part, Rhizoma Cyperi 1-10 part, Radix Salviae Miltiorrhizae 1-10 part, Radix Achyranthis Bidentatae 1-10 part.
4, the preparation of claim 1 is characterized in that, wherein the weight proportion of each component is: Rhizoma Drynariae 1-5 part, Semen Cuscutae 1-5 part, Fructus Psoraleae 1-5 part, Fructus Lycii 1-5 part, Fructus Rubi 1-5 part, Colla Corii Asini 1-5 part, Rhizoma Cyperi 1-5 part, Radix Salviae Miltiorrhizae 1-5 part, Radix Achyranthis Bidentatae 1-5 part.
5, the preparation of claim 1 is characterized in that, wherein the weight proportion of each component is: Rhizoma Drynariae 1-3 part, Semen Cuscutae 1-3 part, Fructus Psoraleae 1-3 part, Fructus Lycii 1-3 part, Fructus Rubi 1-3 part, Colla Corii Asini 1-3 part, Rhizoma Cyperi 1-3 part, Radix Salviae Miltiorrhizae 1-3 part, Radix Achyranthis Bidentatae 1-3 part.
6, the preparation of claim 1 is characterized in that, wherein the weight proportion of each component is: Rhizoma Drynariae 1-2 part, Semen Cuscutae 1-2 part, Fructus Psoraleae 1-2 part, Fructus Lycii 1-2 part, Fructus Rubi 1-2 part, Colla Corii Asini 1-2 part, Rhizoma Cyperi 1-2 part, Radix Salviae Miltiorrhizae 1-2 part, Radix Achyranthis Bidentatae 1-2 part.
7, the preparation of claim 1 is characterized in that, is granule.
8, the preparation method of the preparation of claim 1, it is characterized in that, be to process through extraction or other modes by the raw material of Chinese medicine that above-mentioned prescription is formed, make pharmaceutically active substance, subsequently, with this material is raw material, adds the medicine acceptable carrier when needing, and makes according to the routine techniques of galenic pharmacy.
9, the preparation method of claim 8, it is characterized in that, wherein said active substance is by extracting raw material of Chinese medicine respectively or obtaining by the co-extracted raw material of Chinese medicine, also can obtain by other modes, as: by pulverize, squeeze, calcine, grind, sieve, percolation, extraction, water are carried, alcohol extraction, ester are carried, methods such as ketone is carried, chromatography obtain, these active substances can be the material of extractum form, can be that dry extract also can be a fluid extract, make different concentration according to the different needs decision of preparation.
10, the preparation method of claim 8 is characterized in that, the process following steps: get Colla Corii Asini and be ground into fine powder, and standby; Fructus Psoraleae, Radix Salviae Miltiorrhizae are doubly measured the 60-95% alcohol reflux 2-5 time with 2-10, and each 1-3 hour, filter, merging filtrate, reclaiming ethanol and being concentrated into relative density is 1.20～1.25 clear paste, standby; Rhizoma Cyperi is suitably pulverized, and adds 2-10 times of water gaging, soaks 1-3 hour, adds thermal distillation 3-10 hour and extracts volatile oil, and the aqueous solution after distillation device is in addition collected; The five tastes such as Fructus Psoraleae, Radix Salviae Miltiorrhizae, Rhizoma Cyperi medicinal residues and all the other Rhizoma Drynariae add 4-12 times of water gaging and decoct 2-6 time, decocted 1-4 hour for the first time, decocted 1-6 hour for the second time, collecting decoction, the centrifugal filtration of gradation, filtrate and above-mentioned aqueous solution merge, and it is 1.20～1.25 clear paste that amalgamation liquid is evaporated to relative density, standby; Merge above-mentioned clear paste, mixing is evaporated to relative density and is 1.28～1.30 thick paste, vacuum drying, be ground into fine powder, add donkey-hide gelatin fine powder, dextrin 250g, aspartame 25g, mixing is made granule with 50-95% ethanol, dry, spray into above-mentioned volatile oil, mixing is prepared into pharmaceutical preparation with the galenic pharmacy routine techniques.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610090199 CN1899479A (en) | 2006-07-05 | 2006-07-05 | Chinese medicine compound preparation for treating osteoporosis after menopause and its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610090199 CN1899479A (en) | 2006-07-05 | 2006-07-05 | Chinese medicine compound preparation for treating osteoporosis after menopause and its preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1899479A true CN1899479A (en) | 2007-01-24 |
Family
ID=37655590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610090199 Pending CN1899479A (en) | 2006-07-05 | 2006-07-05 | Chinese medicine compound preparation for treating osteoporosis after menopause and its preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1899479A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102366493A (en) * | 2011-09-30 | 2012-03-07 | 张宁 | Traditional Chinese medicine compound extract for treating postmenopausal osteoporosis and preparation method thereof |
| CN102552766A (en) * | 2012-01-22 | 2012-07-11 | 张小林 | Traditional Chinese medicine used for treating postmenopausal osteoporosis, preparation method thereof, and administration method thereof |
| CN102805781A (en) * | 2012-08-29 | 2012-12-05 | 黄平县润发药业农民专业合作社 | Traditional Chinese medicine for treating kidney-deficiency type lumbocrural pain |
| CN103110719A (en) * | 2012-12-10 | 2013-05-22 | 宋爱民 | Traditional Chinese medicine wine for treating kidney deficiency and essence depletion type osteoporosis |
| CN103330837A (en) * | 2013-07-17 | 2013-10-02 | 王磊 | Traditional Chinese medicine composition for curing osteoporosis of menopausal women |
| CN104161855A (en) * | 2014-08-16 | 2014-11-26 | 逄海东 | Pharmaceutical composition for treating osteoporosis of postmenopausal woman |
| CN104161936A (en) * | 2013-05-16 | 2014-11-26 | 刘克成 | Traditional Chinese medicine composition for preventing and treating postmenopausal osteoporosis and preparation method thereof |
| CN104189693A (en) * | 2014-09-13 | 2014-12-10 | 陈远征 | Traditional Chinese medicine composition for treating posemenopausal osteoporosis |
| CN104706882A (en) * | 2015-02-15 | 2015-06-17 | 陈红 | Traditional Chinese medicine preparation for treating qi stagnancy and blood stasis type postmenopausal osteoporosis |
| CN105106510A (en) * | 2015-08-21 | 2015-12-02 | 青岛金智高新技术有限公司 | Pharmaceutical composition for controlling postmenopausal osteoporosis and application thereof |
-
2006
- 2006-07-05 CN CN 200610090199 patent/CN1899479A/en active Pending
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102366493B (en) * | 2011-09-30 | 2013-07-24 | 张宁 | Traditional Chinese medicine compound extract for treating postmenopausal osteoporosis and preparation method thereof |
| CN102366493A (en) * | 2011-09-30 | 2012-03-07 | 张宁 | Traditional Chinese medicine compound extract for treating postmenopausal osteoporosis and preparation method thereof |
| CN102552766A (en) * | 2012-01-22 | 2012-07-11 | 张小林 | Traditional Chinese medicine used for treating postmenopausal osteoporosis, preparation method thereof, and administration method thereof |
| CN102805781A (en) * | 2012-08-29 | 2012-12-05 | 黄平县润发药业农民专业合作社 | Traditional Chinese medicine for treating kidney-deficiency type lumbocrural pain |
| CN102805781B (en) * | 2012-08-29 | 2014-06-11 | 黄平县润发药业农民专业合作社 | Traditional Chinese medicine for treating kidney-deficiency type lumbocrural pain |
| CN103110719A (en) * | 2012-12-10 | 2013-05-22 | 宋爱民 | Traditional Chinese medicine wine for treating kidney deficiency and essence depletion type osteoporosis |
| CN103110719B (en) * | 2012-12-10 | 2014-07-16 | 宋爱民 | Traditional Chinese medicine wine for treating kidney deficiency and essence depletion type osteoporosis |
| CN104161936A (en) * | 2013-05-16 | 2014-11-26 | 刘克成 | Traditional Chinese medicine composition for preventing and treating postmenopausal osteoporosis and preparation method thereof |
| CN104161936B (en) * | 2013-05-16 | 2017-03-29 | 刘克成 | A kind of Chinese medicine composition of prevention and treatment postmenopausal osteoporosiss and preparation method thereof |
| CN103330837B (en) * | 2013-07-17 | 2014-11-19 | 山东大学齐鲁医院 | A traditional Chinese medicine composition for treating postmenopausal women's osteoporosis |
| CN103330837A (en) * | 2013-07-17 | 2013-10-02 | 王磊 | Traditional Chinese medicine composition for curing osteoporosis of menopausal women |
| CN104161855A (en) * | 2014-08-16 | 2014-11-26 | 逄海东 | Pharmaceutical composition for treating osteoporosis of postmenopausal woman |
| CN104189693A (en) * | 2014-09-13 | 2014-12-10 | 陈远征 | Traditional Chinese medicine composition for treating posemenopausal osteoporosis |
| CN104189693B (en) * | 2014-09-13 | 2017-02-15 | 青岛辰达生物科技有限公司 | Traditional Chinese medicine composition for treating posemenopausal osteoporosis |
| CN104706882A (en) * | 2015-02-15 | 2015-06-17 | 陈红 | Traditional Chinese medicine preparation for treating qi stagnancy and blood stasis type postmenopausal osteoporosis |
| CN105106510A (en) * | 2015-08-21 | 2015-12-02 | 青岛金智高新技术有限公司 | Pharmaceutical composition for controlling postmenopausal osteoporosis and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1899479A (en) | Chinese medicine compound preparation for treating osteoporosis after menopause and its preparation | |
| CN1188159C (en) | Medicines composition for treating coronary heart disease ventricular premature beat and its prepn | |
| CN1150019C (en) | Medicine for treating hecrosis of femoral head | |
| CN1224614A (en) | Medicine for preventing and curing cardiac and cerebral vascular diseases and its preparation | |
| CN101062080A (en) | Medicinal composition for relieving fatigue and preparing process thereof | |
| CN1284567C (en) | Medicinal solution for treating osteoporosis and preparation method thereof | |
| CN102671178B (en) | Preparation method of Chinese medicinal composition for treating nephrotic syndrome and uremia and application thereof | |
| CN1245173C (en) | Medicine composition for treating liver fibrillation and liver cirrhosis and its prepn process | |
| CN1209133C (en) | Medicine for preventing and curing rachitis and osteoporosis and method for preparing the same | |
| CN1931280A (en) | Medicine for treating osteoporosis and its prepn process | |
| CN1051471C (en) | A kind of pharmaceutical composition for treating osteoporosis | |
| CN1857684A (en) | Compound Chinese medicine preparation for removing toxic matter, dispersing blood clots and strengthing body's resistance and its preparaing process | |
| CN1785391A (en) | Chinese medicinal composition and its preparation method | |
| CN1876148A (en) | A Chinese medicinal composition for replenishing kidney and strengthening bone and preparation method thereof | |
| CN1282475C (en) | Combination of medication for treating gallbladder disease and preparation method | |
| CN1226044C (en) | Oral liquid for relieving rheumatic pains and stopping itch, and its preparation method | |
| CN1839999A (en) | Preparation for treating osteoporosis and preparation method thereof | |
| CN1314414C (en) | Chinese traditional medicine for preventing and treating osteoporosis and its preparation process | |
| CN1168473C (en) | Chinese medicine prepn for treating arterioscleriosis | |
| CN1911420A (en) | Compound medicine prepn. for treating osteoporosis, and its prepn. method | |
| CN1126558C (en) | Medicine for treating kidney damage caused by immunological disease lupus erythematosus | |
| CN1186036C (en) | Diabetes treating medicine and its prepn | |
| CN1205989C (en) | Medicine composition for treating ischemic necrosis of femur head and preparing process thereof | |
| CN102988680A (en) | Preparation method of medicinal composition for tonifying kidney and spleen, preventing and treating osteoporosis | |
| CN1814122A (en) | Medicine for treating osteoporosis and preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20070124 |